PRESS RELEASES

Date	Title
Jul 1, 2022	Ardelyx, Inc. Reports Employment Inducement Grants
Jun 30, 2022	Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
Jun 21, 2022	Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
Jun 3, 2022	Ardelyx to Present at the Jefferies 2022 Healthcare Conference
May 24, 2022	Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 17, 2022	Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
May 16, 2022	Ardelyx, Inc. Reports Employment Inducement Grants
May 5, 2022	Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
Apr 28, 2022	Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022
Apr 25, 2022	Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com